সি-ফেনাক

WvB‡K¬v‡dbvK †mvwWqvg
U¨ve‡jU/wUAvi K¨vcmyj/Bb‡RKkb

বর্ণনা

wm-‡dbvK nj WvB‡K¬v‡dbv‡Ki GKwU bb‡÷iqWvj cÖ¨´wZ hv A¨vw›U-Bbd¬¨v‡gUwi G‡R›U hv‡Z wPwýZ †e`bvbvkK, cÖ`vn we‡ivax Ges A¨vw›UcvB‡iwUK ˆewkó¨ i‡q‡Q|

কর্মপ্রক্রিয়া

mvB‡K¬v-Aw·wR‡bR GbRvB‡gi wbw`©ó Bbwnwek‡bi gva¨‡g †cÖv÷vMø¨vwÛb ms‡kø‡l‡Y evav †`Iqvi d‡j WvB‡K¬v‡dbv‡Ki cÖ`vn-we‡ivax, e¨_vbvkK Ges A¨vw›UcvB‡iwUK ˆewkó¨¸‡jv N‡U e‡j aviYv Kiv nq|

ফার্মাকোকাইনেটিক্স

Iivj GWwgwb‡÷ªk‡bi c‡i WvB‡K¬v‡dbvK M¨v‡÷ªvBb‡U÷vBbvj Uª¨v± †_‡K fvjfv‡e †kvwlZ nq, Z‡e G‡›UwiK †Kv‡UW cÖ¨´wZ _vK‡j m‡e©v"P cøvRgv Nb‡Zi mgq cwiewZ©Z n‡Z cv‡i| wKQz c~e©eZ©x wm‡÷wgK Gwjwg‡bkb i‡q‡Q wKš' Iivj †Wv‡Ri cÖvq 60% wm‡÷wgK mÂvj‡b †cŠuQvq| m‡e©v"P cøvRgv †j‡fj GWwgwb‡÷ªk‡bi 2 NÈvi (mxgv 1-4 NÈv) g‡a¨ AwR©Z nq| 75 wgMÖv Bb‡RKk‡bi †WvR AbymiY K‡i, m‡e©v"P cøvRgv NbZ¡ 10-22 wgwb‡Ui g‡a¨ †cŠuQv‡bv hvq| GWwgwb÷viK…Z †Wv‡Ri cÖvq 60% wKWwbi gva¨‡g †gUv‡evjvBUm wn‡m‡e Zv‡`i Møy‡Kv‡ivbvBW ev mvj‡dU KbRy‡MU wn‡m‡e wbM©Z nq Ges 1% Gi I Kg AcwiewZ©Z AvKv‡i wbM©Z nq| Mo nvd jvBd nj 1-2 NÈv|

উপাদান

wm-‡dbvK 50 wgMÖv U¨ve‡jU: cÖwZwU G‡›UwiK-‡Kv‡UW U¨ve‡j‡U i‡q‡Q WvB‡K¬v‡dbvK †mvwWqvg wewc 50 wgMÖv|
wm-‡dbvK wU Avi 100 wgMÖv K¨vcmyj: cÖwZwU K¨vcmyj i‡q‡Q WvB‡K¬v‡dbvK †mvwWqvg wewc 100 wgMÖv|
wm-‡dbvK 75 wgMÖv Bb‡RKkb: cÖwZ 3 wgwj G¨v¤úy‡j i‡q‡Q WvB‡K¬v‡dbvK †mvwWqvg wewc 75 wgMÖv|
wm-‡dbvK cøvm AvBGg Bb‡RKkb: cÖwZ 2 wgwj G¨v¤úy‡j i‡q‡Q WvB‡K¬v‡dbvK †mvwWqvg wewc 75 wgMÖv Ges wj‡Wv‡KBb nvB‡Wªv‡K¬vivBW BDGmwc 20 wgMÖv|

নির্দেশনা

wiDgvU‡qW Av_ª©vBwUm, Aw÷IAv_ª©vBwUm, wc‡Vi wb¤œevs‡k e¨_v Ges Ab¨vb¨ Zxeª †ckx Ges K¼v‡ji e¨vwa †hgb wngvwqZ Kvua, †UwÛbvBwUm, †U‡bvmvB‡bvfvBwUm, evimvBwUm, gP‡K hvIqv, †÷ªb Ges ¯'vbPz¨wZ, A¨vbKvB‡jvwRs ˆúwÛjvBwUm, Zxeª evZRwbZ e¨_v, A‡_©v‡cwWK‡m e¨_v, †W›Uvj Ges Ab¨vb¨ gvBbi Acv‡ik‡b|

ডোজ এবং এডমিনিস্ট্রেশন

wm-‡dbvK 50 wgMÖv G‡›UwiK †Kv‡UW U¨ve‡jU:
প্রাপ্তবয়স্কদের ক্ষেত্রে
†gvU 75-125 wgMÖv ˆ`wbK `yBwU ev wZbwU wef³ †Wv‡R †`Iqv nq|
wm-‡dbvK wUAvi K¨vcmyj: cÖwZw`b GKwU K¨vcmyj, cvwbi mv‡_ m¤ú~Y© MÖnY Kiv nq, we‡klZ Lvev‡ii mgq| cÖ‡qvR‡b, cÖPwjZ K¨vcmy‡ji mv‡_ m¤ú~iK K‡i ˆ`wbK †WvR 150 wgMÖv evov‡bv †h‡Z cv‡i|
শিশুদের ক্ষেত্রে
G‡›UwiK †Kv‡UW U¨ve‡jU: wef³ gvÎvq cÖwZw`b 1-3 wgMÖv/‡KwR|
wm-‡dbvK wUAvi K¨vcmyj: cÖ¯ÍvweZ bq|
বয়স্কদের ক্ষেত্রে
eq¯‹ ev `ye©j †ivMx‡`i †ÿ‡Î me©wb¤œ Kvh©Ki †WvR mycvwik Kiv nq, hw`I eq¯‹ †ivMx‡`i †ÿ‡Î WvB‡K¬v‡dbvK †mvwWqv‡gi dvg©v‡KvKvB‡bwU· †Kv‡bv wK¬wbK¨vwj cÖvmw½K gvÎvq ÿwZMÖ¯Í nq bv|
wm-‡dbvK Bb‡RKkb/wm-‡dbvK cøvm Bb‡RKkb
cÖvßeq¯‹‡`i †ÿ‡Î: B›Uªvgvm Kzjvi Bb‡RKkb Øviv cÖwZw`b GKevi (ev ¸iæZi †ÿ‡Î, `yevi) GKwU G¨v¤úyj|
†ibvj †KvwjK: cÖwZw`b GKevi B›Uªvgvm Kzjvifv‡e GKwU G¨v¤úyj| cÖ‡qvR‡b, 30 wgwbU c‡i AvIl G¨v¤úyj †`qv †h‡Z cv‡i| WvB‡K¬v‡dbv‡Ki cÖ¯ÍvweZ me©vwaK ˆ`wbK †WvR nj 150 wgMÖv †h †Kv‡bv iæ‡U| wj‡Wv‡KB‡bi cÖ¯ÍvweZ me©vwaK ˆ`wbK †WvR nj 200 wgMÖv|
wkï‡`i †ÿ‡Î: Ry‡fbvBj `xN©¯'vqx Av_ª©vBwU‡m, 1-3 wgMÖv WvB‡K¬v‡dbvK/‡KwR IR‡b ˆ`wbK wef³ gvÎvq|
eq¯‹‡`i †ÿ‡Î: eq¯‹ ev `ye©j †ivMx‡`i †ÿ‡Î, eqm Ges kvixwiK Ae¯'vi mv‡_ mvgÄm¨c~Y©, me©wb¤œ Kvh©Ki †WvR cÖ¯ÍvweZ|

প্রতিনির্দেশনা

c~‡e© WvB‡K¬v‡dbvK e¨env‡i AwZ ms‡e`bkxjZv Av‡Q, nvucvwb Ges hviv Gmwcwib ev Ab¨vb¨ GbGmGAvBwW Øviv k¦vmKó, AvwU©‡Kwiqv ev Zxeª ivBbvBwU‡m AvµvšÍ nq Zv‡`i †ÿ‡Î wm-‡dbvK wb‡`©wkZ nq bv|

সতর্কতা

wm-‡dbvK Mf©eZx gwnjv‡`i Rb¨ wb‡`©wkZ nq bv hw` bv GwU MÖnY Kivi eva¨Zvg~jK KviY _v‡K| cvK¨´jxi ÿZ, ewgi mv‡_ i³ wbM©Z nIqv, M¨v‡÷ªvBb‡U÷vBbvj †Kvj‡bi g‡a¨ i³cvZ, i³ÿiY Wvqv‡_wmm ev ¸iæZi hK…Z I g~Ívk‡qi AcÖvPzh©Zvi BwZnvm _vK‡j †ivMx‡`i wbweo ch©‡eÿ‡Y ivLv DwPZ| hw` hK…‡Zi wµqvi A¯^vfvweKZv Ae¨vnZ _v‡K ev Lvivc nq, wK¬wbKvj jÿY Ges DcmM©¸‡jv hK…‡Zi †iv‡Mi mv‡_ mvgÄm¨c~Y© nq ev hw` Ab¨vb¨ cÖKvk N‡U (BIwm‡bvwdwjqv, dzmKzwo), ZLb wm-‡dbvK eÜ Kiv DwPZ| hK…‡Z GbRvB‡gi cwigvY K‡g hvIqv †ivMx‡`i †ÿ‡Î wm-‡dbvK e¨envi Avµg‡Yi KviY n‡Z cv‡i|

পার্শ্ব প্রতিক্রিয়া

GwcM¨vw÷ªK RbxZ e¨_v, ewg ewg fve Ges Wvqwiqv, gv_ve¨_v Ges mvgvb¨ gv_v †Nviv wKQz wKQz †ivMx‡`i Øviv Awfhy³ nq| G¸‡jv cÖvqkB ÿY¨´vqx Ges Ily‡ai avivevwnKZvq wbeviY n‡q hvq| gv‡S gv‡S Zj‡Ki dzmKzwo, Zj‡Ki wUmy¨ dz‡j hvIqv Ges hK…‡Z wmivg UªvÝwg‡bR GbRvB‡gi A¯^vfvweK cÖvPzh©Zvi jÿY †`Lv hvq| LyeB Kg cvk¦© cÖwZwµqvi g‡a¨ i‡q‡Q cvK¨´jxi ÿZ mwµqKiY mn ewgi mv‡_ i³ wbM©Z nIqv, M¨v‡÷ªvBb‡U÷vBbvj †Kvj‡bi g‡a¨ i³cvZ, i‡³i e¨vwa (e¨vcK e¨env‡i)| GQvovI A¨vbvdvBj¨vKU‡qW cÖwZwµqvi wKQz wew"Qbœ cÖwZ‡e`b cvIqv hvq|

গর্ভাবস্থা এবং স্তন্যদানকালে ব্যবহার

Mf©ve¯´vq WvB‡K¬v‡dbvK e¨envi Kiv DwPZ bq, hw` bv GwU e¨envi Kivi eva¨Zvg~jK KviY _v‡K| G‡ÿ‡Î me©wb¤œ Kvh©Ki †WvR e¨envi Kiv DwPZ| Mf©ve¯´vi †kl ˆÎgvwm‡Ki mgq GB ai‡bi Ilya e¨envi cÖ¯ÍvweZ bq| LyeB Kg cwigv‡Y WvB‡K¬v‡dbvK ey‡Ki `y‡a kbv³ Kiv †h‡Z cv‡i, Z‡e wkïi Dci Gi †Kvb AevwÃZ cÖfve Avkv Kiv nq bv|

ড্রাগ মিথস্ক্রিয়া

A¨vwmUvBj m¨vwjmvBwjK Gwm‡Wi mv‡_ GK‡hv‡M MÖnY Ki‡j G‡K Ac‡ii cøvRgv NbZ¡‡K n«vm K‡i| WvB‡K¬v‡dbvK, WvBMw·b, †g‡_v‡Uª‡·‡Ui cøvRgv NbZ¡ evovq Ges g~Îea©K¸‡jvi Kvh©Kjvc‡K we‡ivwaZv K‡i Ges GbGmGAvBwW Øviv wKWwbi welv³Zvi SzuwK e„w× cvq| GbGmGAvBwW Øviv mvj‡dvbvBj BDwiqvi Kg©ÿgZv e„w× cvq|

মাত্রা

cÖ¯ÍZKviK :
Av‡jvi Av`ª©Zx‡_ ‡K `~‡i, 30° †mjwmqvm Zvcgv Îvi g‡a¨ msiÿY Kiæb| mKj Ilya wkï‡`i bvMv‡ji evB‡i ivLyb|
[redacted] K‡jR †jvK cwikvi evsjv‡`k|
[redacted] weø÷vi Kiv 10×10 U¨ve‡jU _v‡K|

C-Fenac

Diclofenac Sodium
Tablet/TR Capsule/Injection

Description

C-Fenac is a preparation of Diclofenac is a non-steroidal anti-inflammatory agent with marked analgesic, anti-inflammatory and anti-pyretic properties.

Mode of action

Anti-inflammatory, analgesic and anti-pyretic properties of diclofenac are thought to occur as a result of inhibition of prostaglandin synthesis by selective inhibition of cyclo-oxyginase enzyme.

Pharmacokinetics

Diclofenc is well absorbed from GI tract after oral administration, but with enteric-coated preparation, the time to peak plasma concentration can be variable. There is some presystemic elimination but about 60% of the oral dose reaches the systemic circulation. Peak plasma level achieved within 2 hours (range 1-4 hrs) after administration. Following a dose of 75 mg injection, peak plasma concentrations are reached within 10-22 minutes. Approximately 60% of administered dose is excreted via the kidneys in the form of metabolites as their glucuronide or sulphate conjugates and less than 1% in unchanged form. The mean elimination half-life is 1-2 hrs.

Composition

C-Fenac 50mg Tablet: Each enteric-coated tablet contains Diclofenac Sodium BP 50mg.
C-Fenac TR 100mg Capsule: Each Capsule contains Diclofenac Sodium BP 100mg.
C-Fenac 75mg Injection: Each 3ml ampoule contains Diclofenac Sodium BP 75mg.
C-Fenac Plus IM Injection: Each 2ml ampoule contains Diclofenac Sodium BP 75mg and Lidocaine Hydrochloride USP 20mg.

Indications

Rheumatoid arthritis, osteoarthritis, low back pain and other acute musculo-skeletal disorders such as frozen shoulder, tendinitis, tenosynovitis, bursitis, sprain, strain and dislocation, ankylosing spondylitis, acute gout, pain in orthopaedics, dental and other minor surgery.

Dosage and Administration

C-Fenac 50 mg enteric coated tablets:

Adults

A total of 75-150 mg daily given in two or three divided doses. C-Fenac TR capsule: One capsule daily, taken whole with liquid, preferably during meal. If necessary, the daily dose can be increased to 150 mg by supplementation with conventional capsule.

Children

Enteric coated tablet: 1-3 mg/kg per day in divided doses. C-Fenac TR Capsule: Not recommended.

Elderly patients: In elderly or debilitated patients, the lowest effective dosage is recommended, although the pharmacokinetics of diclofenac sodium are not impaired to any clinically relevant extent in elderly patients.

C-Fenac injection/C-Fenac Plus injection :

Adults: One ampoule once (or in severe cases, twice) daily by intramuscular injection.
Renal colic: One ampoule once daily intramuscularly. A further ampoule may be administered after 30 minutes, if necessary. The recommended maximum daily dose of diclofenac is 150 mg, by any route. The recommended maximum daily dose of lidocaine is 200mg. Children: In juvenile chronic arthritis, 1-3 mg of diclofenac/kg body wt. daily in divided doses.
Elderly patients: In elderly or debilitated patients, the lowest effective dosage is recommended, commensurate with age and physical status.

Contraindication

C-Fenac should not be given in patients with previous hypersensitivity to Diclofenac, asthmatic patients and in whom attacks of asthma, urticaria or acute rhinitis are precipitated by Aspirin or other NSAIDs.

Precautions

C-Fenac should not be prescribed to pregnant women unless there is compelling reason for doing so. Patients with a history of peptic ulcer, haematemesis, melaena, bleeding diathesis or with severe hepatic or renal insufficiency, should be kept under close surveillance. If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver diseases or if other manifestations occur (eosinophilia, rash), C-Fenac should be discontinued. Use of C-Fenac in patients with hepatic prophyria may trigger an attack.

Side Effects

Epigastric pain, nausea and diarrhoea, headache and slight dizziness may be complained by some patients. These are often transient, disappearing with continuation of medication. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported. Very rarely reported side effects include activation of peptic ulcer. haematemesis or melaena. blood dyscrasia (in course of extensive usage). There have been isolated reports of anaphylactoid reactions.

Use in pregnancy & lactation

Diclofenac should not be used during pregnancy, unless there are compelling reasons for doing so. The lowest effective dose should be used. These types of drugs are not recommended during the last trimester of pregnancy. Very small quantities of diclofenac may be detected in breast milk, but no undesirable effects on the infant are to be expected.

Drug interactions

Concomitant ingestion with acetylsalicylic acid lowers the plasma concentration of each other. Diclofenac increases the plasma concentrations of digoxin, methotrexate and antagonize the activity of diuretics and the risk of nephrotoxicity of NSAID is-increased. Activity of sulfonylureas is increased by NSAIDS.

Storage

Store at temperature within 30°C, protected from light & moisture. Keep out of the reach of children.

Packaging

C-Fenac 50 mg Tablet: Box containing 10x10 tablets in blister pack.
C-Fenac TR 100mg Capsule: Box containing 10x10 capsules in blister pack.
C-Fenac 75mg Injection: Box containing 10 ampoules of 3 ml.
C-Fenac Plus IM Injection: Box containing 20 ampoules of 2 ml.

Manufactured by:

Chemist Laboratories Ltd.
College Row, Barishal, Bangladesh.